EW vs ZBH stock comparison
Edwards Lifesciences vs. Zimmer Biomet · data as of November 13, 2026
Edwards Lifesciences (EW) has a market value of about $61.6B, Zimmer Biomet (ZBH) about $19.5B. Over their latest twelve months Edwards Lifesciences had revenue of $6.7B and Zimmer Biomet $8.6B.
On our five checks Edwards Lifesciences scores higher: 2.8 out of 5 (average) against 2.2 (weak).
By area, the stronger company is Zimmer Biomet on value; Edwards Lifesciences on future growth; Edwards Lifesciences on track record; Edwards Lifesciences on financial health; Zimmer Biomet on shareholder returns.
Zimmer Biomet is cheaper on earnings (P/E 26.1 vs. 60.5), while Edwards Lifesciences grew revenue faster over five years (6.7% vs. 6.1% a year).
Edwards Lifesciences leads on 11 of the compared lines and Zimmer Biomet on 12.
Side by side
| EW | ZBH | |
|---|---|---|
| Size and price | ||
| Market cap | $61.6B | $19.5B |
| Share price | $107.15 | $103.21 |
| Score | ||
| Overall score (of 5) | 2.8 | 2.2 |
| Value | 0 | 1 |
| Future growth | 4 | 1 |
| Track record | 2 | 1 |
| Financial health | 5 | 3 |
| Shareholder returns | 3 | 5 |
| Valuation | ||
| P/E (TTM) | 60.5 | 26.1 |
| Forward P/E | 33.5 | 11.4 |
| Price / free cash flow | 43.3 | 11.9 |
| Price / sales | 9.2 | 2.3 |
| EV / EBITDA | 35.8 | 11.7 |
| PEG | 8.55 | — |
| DCF value vs. price | −64% | −12% |
| Business | ||
| Revenue | $6.7B | $8.6B |
| Net income | $1.0B | $767M |
| Free cash flow | $1.4B | $1.6B |
| Net margin | 15.3% | 9.0% |
| Gross margin (5-yr avg.) | 79.6% | 71.0% |
| ROIC (5-yr avg.) | 16.0% | 4.8% |
| Growth | ||
| Revenue growth (1 yr) | 11.6% | 7.2% |
| Revenue growth (5 yrs, per year) | 6.7% | 6.1% |
| EPS growth (5 yrs, per year) | 7.1% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | $3.9B | -$7.1B |
| Dividend yield | None | 0.93% |
| Shareholder yield | 1.5% | 3.4% |
| Analysts | ||
| Upside to average target | +6% | +13% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: EW TTM to September 30, 2026, ZBH TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Edwards Lifesciences or Zimmer Biomet?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Edwards Lifesciences scores 2.8 out of 5 and Zimmer Biomet 2.2; the table shows where each one is stronger.
Is Edwards Lifesciences cheaper than Zimmer Biomet?
On trailing earnings, Zimmer Biomet trades at a P/E of 26.1 and Edwards Lifesciences at 60.5, so Zimmer Biomet is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Edwards Lifesciences or Zimmer Biomet?
Over five years Edwards Lifesciences grew revenue about 6.7% a year and Zimmer Biomet about 6.1% a year.
Which pays a higher dividend?
Edwards Lifesciences yields nothing (no dividend) and Zimmer Biomet 0.93%.
Full Edwards Lifesciences analysis → Full Zimmer Biomet analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.